Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance

Expands R&D Operations with New Austin, TX Facility

Recent Feasibility Work Confirms Utility of Thin Film Freezing in Developing Next- Generation Vaccines

Conference Call and Webcast Scheduled Today, Thursday, August 11, 2022, at 4:30 PM ET

FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Thursday, August 11, 2022, at 4:30 PM ET.

“We enter the second half of 2022 with significant momentum based upon the continued advancement of our internal pipeline coupled with growing recognition that our Thin Film Freezing technology has the potential to revolutionize drug delivery across a diverse array of molecules,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “We have initiated Phase 2 studies for our two lead internal product candidates, Inhaled Voriconazole Powder (TFF VORI) and Inhaled Tacrolimus Powder (TFF TAC), and we are engaged in active outreach with a number of companies that have expressed interest in these two innovative programs. Importantly, the VORI and TAC programs also serve to further validate the clinical utility of Thin Film Freezing technology, sending a clear signal to the industry that applications of our technology continue to grow and advance further into human testing.

“Our partnering activity also remains robust, and we are now working with three additional top 20 pharma companies. With more than 20 disclosed collaborations and well over 50 material transfer agreements, we continue to make significant progress

with our industry and academic partners, consistently demonstrating how Thin Film Freezing offers a unique and versatile solution for significantly improving formulations for safer, more targeted drug delivery. We expect many of these programs to advance further into preclinical and clinical testing later this year. As the success of our partnerships continues to grow, we also anticipate that many of our existing partners will expand their relationship with TFF as well as open up the opportunity for developing new relationships.

“To accommodate current and future demand for Thin Film Freezing partnerships, in July we announced the opening of a new R&D facility located in Austin, Texas that provides us with significantly more laboratory space. This 3,500 square feet facility includes a dedicated lab for downstream processing of preclinical products created via Thin Film Freezing, which will complement the company’s existing formulation development capabilities. As TFF expands its in-house and partnered research, including applications in biologics, the Austin facility will also allow us to accommodate larger equipment to facilitate scale-up and manufacturing for preclinical studies.

“A major reason for our R&D expansion also relates to the increased feasibility work surrounding our next-generation vaccine programs. There is a growing body of scientific evidence suggesting that, when compared to conventional delivery, mucosal-based delivery of vaccines may reduce the burden of infectious diseases by providing first-line protection at viral entry points.1 We have successfully completed multiple feasibility studies with Thin Film Freezing demonstrating how our unique, dry powder-based formulations can be successfully delivered to both lung and nasal regions to elicit a robust host immune response. As this area of work continues to grow, we look forward to providing additional updates on our vaccine applications later this year.

“We have recently delivered the final published clinical study report for Inhaled Niclosamide Powder to our partner, UNION Therapeutics. Union is working diligently to provide TFF with feedback on their option to license Niclosamide Inhalation Powder. We continue to believe that the widespread availability of potent antiviral medicines is key to significantly lowering mortality and morbidity associated with COVID-19 infection.

“We believe the second half of the year is shaping up to be a very exciting period for TFF Pharmaceuticals. As a reminder, we spent the first half of 2022 positioning the company for significant growth by advancing our two lead pipeline assets into Phase 2 testing, forging important new strategic alliances, expanding the applications of our technology platform across a wide spectrum of molecules, and making key senior level appointments to help drive our growth while optimizing our capital and operational efficiencies. We look forward to announcing additional progress throughout the remainder of 2022.”

Conference Call and Webcast Information

The Company will host a conference call today, Thursday, August 11, 2022, at 4:30 PM, Eastern Time, to review the clinical, corporate and financial highlights. To participate in the conference call, please dial the following numbers prior to the start of the call:

  Domestic Dial-In Number: Toll-Free: 1-855-327-6837  
  International Dial-In Number: 1-631-891-4304  
  Conference ID: 10019661  

The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals’ Website, or directly at

Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors section.

Recent Clinical and Corporate Highlights:

  • In July, the Company announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. The new facility of over 3,500 square feet significantly increases TFF’s total lab space, adding a dedicated lab for downstream processing of products created via Thin Film Freezing, which will complement the company’s existing formulation development capabilities. The new space will be supervised by Donald Owens, Ph.D., Director of Product Development at TFF, and supported by John Koleng, Ph.D., R.Ph., Vice President of Product Development and Manufacturing. The company also plans to expand the product development team in Austin, which will be based at the new facility, to support the growing number of partnered projects.

Strategic Business Development and Partnership Activities – Biopharmaceutical Companies and Research Institutions:

  • In July, Dr. Bill Williams, co-inventor of the Thin Film Freezing technology, published an editorial review article in Biopharm International entitled, “Improved Formulations to Enable Stable Delivery of Biologics”. The article highlights the significant advantages of Thin Film Freezing over conventional freeze-drying processes, including improvements with respect to less particle aggregation and less protein denaturation, which can overcome challenges in the formulation and delivery of biologics.
  • In May, the Company announced multiple presentations highlighting the broad applicability of its Thin Film Freezing Technology at the Respiratory Drug Delivery Meeting (RDD). Dr. Williams delivered a platform presentation with data on stabilizing and delivering antivirals, antibodies and vaccines using Thin Film Freezing technology in the fight against COVID-19 and other serious viral infections. Additionally, Dr. Williams and his colleagues presented five posters highlighting the broad applicability of Thin Film Freezing to improve drug development of biologics and small molecules for respiratory diseases, including pulmonary fibrosis and COVID-19. The findings from Dr. Williams’ lab also highlighted how Thin Film Freezing can be used to facilitate delivery of other treatment modalities, such as gene therapy.
  • In April, the Company announced safety and pharmacokinetic data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed as a potential treatment for COVID-19. The data showed that Niclosamide Inhalation Powder was well tolerated with no serious adverse events across all subject cohorts. TFF Pharmaceuticals believes the 6 mg dose level of Niclosamide Inhalation Powder is estimated to produce a concentration of >100 μM in the epithelial lining fluid in the lung following delivery as a dry powder, which would be considered highly potent with respect to inhibiting viral replication. A single administration of 6 mg of Niclosamide Inhalation Powder to the lungs provided equal mean maximum drug concentration (Cmax) in the blood as 100 mg delivered as a nebulized spray to the lungs and nasal cavity, as demonstrated in a recent publication.2

Financial Results

For the quarter ended June 30, 2022, compared to quarter ended June 30, 2021

  • Cash Position: As of June 30, 2022, TFF Pharmaceuticals reported cash and cash equivalents of $20.9 million.
  • Research and Development (R&D) expenses: R&D expenses for the second quarter of 2022 were $5.1 million, compared to $2.8 million in 2021.
  • General & Administrative (G&A) expenses: G&A expenses for the second quarter of 2022 were $3.7 million, compared to $2.4 million in 2021.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the second quarter of 2022 of $8.7 million, compared to a net loss of $4.7 million in 2021.

TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as 75% of the dose to the deep lung. Thin Film Freezing does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of Thin Film Freezing can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products.


TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert any drug, including vaccines, small and large molecules and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at


This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the expectations for its continued development of Inhaled Tacrolimus and

Voriconazole Powders, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its Inhaled Tacrolimus, Voriconazole Powders or any of its dry powder product candidates, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s 2021 Annual Report on Form 10-K filed with the SEC on March 24, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.



Investor Relations Contact:
Corey Davis, Ph.D. LifeSci Advisors

Media Contact:
Gwendolyn Schanker LifeSci Communications
(269) 921-3607

    Three Months     Three Months     Six Months     Six Months  
Ended Ended Ended Ended
June 30, June 30, June 30, June 30,
2022 2021 2022 2021
Grant revenue   $ 28,004     $ 1,850     $ 95,439     $ 26,165  
Operating expenses:                                
Research and development     5,110,805       2,762,170       10,372,409       8,040,422  
General and administrative     3,690,010       2,351,007       6,936,205       4,998,422  
Total operating expenses     8,800,815       5,113,177       17,308,614       13,038,844  
Loss from operations     (8,772,811 )     (5,111,327 )     (17,213,175 )     (13,012,679 )
Other income:                                
Other income     20,606       441,546       77,783       672,824  
Interest income     5,880       14,069       13,065       29,568  
Total other income     26,486       455,615       90,848       702,392  
Net loss   $ (8,746,325 )   $ (4,655,712 )   $ (17,122,327 )   $ (12,310,287 )
Net loss per share, basic and diluted   $ (0.34 )   $ (0.18 )   $ (0.67 )   $ (0.51 )
Weighted average common shares     25,373,706       25,369,144       25,372,749       24,261,032  
outstanding, basic and diluted
    June 30,     December 31,  
2022 2021
Current assets:                
Cash and cash equivalents   $ 20,890,253     $ 33,794,672  
Receivable due from collaboration agreement     1,812,975       1,628,703  
Research and development tax incentive receivable     994,549       966,646  
Prepaid assets and other current assets     1,483,953       2,447,930  
Total current assets     25,181,730       38,837,951  
Operating lease right-of-use asset, net     232,138        
Property and equipment, net     2,332,254       1,859,860  
Other assets     167,077        
Total assets   $ 27,913,199     $ 40,697,811  
Current liabilities:                
Accounts payable   $ 3,480,461     $ 1,493,842  
Accrued compensation           416,910  
Deferred research grant revenue     268,000       50,000  
Current portion of operating lease liability     79,050        
Total current liabilities     3,827,511       1,960,752  
Operating lease liability, net of current portion     146,188        
Total liabilities     3,973,699       1,960,752  
Commitments and contingencies                
Stockholders’ equity:                
Common stock     25,374       25,372  
Additional paid-in capital     106,461,934       104,078,968  
Accumulated other comprehensive loss     (107,121 )     (48,921 )
Accumulated deficit     (82,440,687 )     (65,318,360 )
Total stockholders’ equity     23,939,500       38,737,059  
Total liabilities and stockholders’ equity   $ 27,913,199     $ 40,697,811